Common grade 3 to 4 AEs were consistent with the known safety profiles of bosutinib; these included skin rash (26%), increased AST (9%), and increased ALT (20%); there were no differences in grade 3–4 skin rash (p = 1.00), increased AST (p = 0.690), and increased ALT (p = 0.554) between the present study and the previous the Japanese phase 1/2 study; the incidence of diarrhea was low (3% vs. 25% in the Japanese phase 1/2 study; p = 0.018)). The gene discussed is GPT; the disease is Skin rash.